The Food and Drug Administration (FDA) has licensed a bivalent human papillomavirus (HPV) vaccine (Cervarix, GlaxoSmithKline Biologicals; HPV2) for girls and women for prevention of cervical cancer and related disorders caused by HPV types 16 and 18. It also has expanded the indications for the quadrivalent HPV vaccine (Gardasil, Merck and Co. Inc.; HPV4) to include prevention of genital warts caused by HPV types 6 and 11 in boys and men.

The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) made its recommendations for use of both vaccines on Oct. 21.

HPV2 contains the L1 major capsid proteins of HPV types 16 and 18. Based on results of clinical trials in girls and women, the FDA licensed the vaccine for prevention of cervical cancer, cervical intraepithelial neoplasia (CIN) grade 2 or worse, adenocarcinoma in situ and CIN grade 1, caused by HPV types...

You do not currently have access to this content.